OMERNasdaqPharmaceutical PreparationsFiscal year ends December 31

OMEROS CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$16.35+0.15 (+0.93%)

Close on Oct 19, 2026

Market cap: $1.47B
P/E (TTM): –
Dividend yield: –

OMEROS CORP income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q1 2021 2021-03-31	Q4 2020 2020-12-31	Q3 2020 2020-09-30	Q2 2020 2020-06-30	Q1 2020 2020-03-31	Q4 2019 2019-12-31	Q3 2019 2019-09-30	Q2 2019 2019-06-30	Q1 2019 2019-03-31	Q4 2018 2018-12-31	Q3 2018 2018-09-30	Q2 2018 2018-06-30	Q1 2018 2018-03-31	Q4 2017 2017-12-31	Q3 2017 2017-09-30	Q2 2017 2017-06-30	Q1 2017 2017-03-31	Q4 2016 2016-12-31	Q3 2016 2016-09-30	Q2 2016 2016-06-30	Q1 2016 2016-03-31
Revenue	29	9.89	–	–	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	21	11	26	14	24	33	30	27	22	22	4.61	1.66	1.59	14	22	17	12	13	11	10	7.42
Cost of Revenue	0.80	0.59	–	–	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	0.26	0.09	0.40	0.15	0.27	0.40	0.28	0.06	0.13	0.16	0.04	0.12	0.20	0.47	0.18	0.16	0.27	0.38	0.38	0.33	0.33
Gross Profit	28	9.31	–	–	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	21	11	26	13	23	33	30	27	22	22	4.57	1.54	1.39	13	21	17	12	13	11	9.68	7.09
Research & Development	14	13	19	16	22	24	23	24	45	27	29	32	30	25	27	39	24	24	30	33	23	31	24	29	37	24	19	26	25	27	19	18	15	15	13	12	13	12	10	15
Selling, General & Admin	14	13	9.64	10	10	11	10	11	14	12	11	16	11	11	14	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	–	11	11	14	12	14	11	13	13	18	20	17	18	16	17	17	15	15	13	13	11	12	12	16	12	12	10	10	11
Operating Expenses	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	41	40	40	32	29	28	27	29	25	25	23	21	27
Total Costs & Expenses	28	27	29	26	32	35	33	35	59	39	40	48	41	36	40	51	37	35	43	45	44	52	41	47	57	41	36	41	40	40	32	29	–	–	–	–	–	–	–	–
Operating Income	0.07	-17	-29	-26	-32	-35	-33	-35	-59	-39	-40	-48	-41	-36	-40	-51	-37	-35	-43	-45	-34	-25	-28	-24	-24	-11	-9.34	-19	-18	-35	-31	-28	-14	-5.11	-12	-13	-12	-12	-11	-19
Interest Expense	7.59	5.89	8.73	-13	0.02	3.65	3.18	4.05	9.22	8.23	7.06	7.92	7.93	7.93	7.90	4.93	4.93	4.94	4.95	4.90	7.99	6.88	5.98	5.90	5.81	5.72	5.53	5.60	5.15	4.60	3.68	2.83	2.86	2.78	2.72	2.66	2.45	2.14	1.86	1.38
Interest & Investment Income	–	–	–	–	–	0.70	1.30	1.80	2.50	2.80	3.00	4.00	4.20	3.40	2.20	0.40	0.20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.67	0.49	0.53	0.42	0.37	-0.63	0.36	0.55	0.29	0.35	0.42	0.49	0.15	0.57	0.60	0.46	0.43	0.41	0.30	0.30	0.27	0.21	0.17	0.29
Pretax Income	6.67	51	–	–	-26	-38	–	–	–	–	–	–	–	–	–	–	–	–	-105	–	-88	-46	–	–	-112	-16	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	0.03	0.06	–	–	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-15	-7.85	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Continuing Operations	6.64	51	80	-21	-26	-38	-37	-37	-65	-44	-39	-52	-44	-40	-46	-55	-42	-39	-47	-50	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Discontinued Operations	6.60	4.81	6.56	-9.67	0.47	4.11	5.18	4.88	9.08	6.67	30	14	7.00	5.98	175	37	11	6.48	328	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	–	–	–	–	-37	-34	129	-18	-31	-33	281	-35	-37	-38	-33	-29	-29	-16	-14	-24	-24	-39	–	–	–	–	–	–	–	–	–	–
Net Income	13	56	86	-31	-25	-33	-31	-32	-56	-37	-9.07	-38	-37	-34	129	-17	-31	-33	281	-35	-37	-38	-33	-29	-29	-16	-14	-24	-24	-39	-34	-30	-17	-7.48	-14	-15	-20	-14	-13	-21
EPS (Basic)(per share)	0.18	0.78	–	-0.47	-0.43	-0.58	-0.54	-0.56	-0.97	-0.63	-0.15	-0.60	-0.59	-0.54	2.05	-0.28	-0.49	-0.53	4.48	-0.57	-0.60	-0.66	-0.61	-0.53	-0.58	-0.33	-0.29	-0.50	-0.48	-0.81	-0.70	-0.62	-0.34	-0.16	-0.33	-0.34	-0.45	-0.34	-0.32	-0.54
EPS (Diluted)(per share)	0.15	0.62	–	-0.47	-0.43	-0.58	-0.54	-0.56	-0.97	-0.63	-0.15	-0.60	-0.59	-0.54	2.05	-0.28	-0.49	-0.53	4.48	-0.57	-0.60	-0.66	-0.61	-0.53	-0.58	-0.33	-0.29	-0.50	-0.48	-0.81	-0.70	-0.62	-0.34	-0.16	-0.33	-0.34	-0.45	-0.34	-0.32	-0.54
Shares Outstanding (Basic, Weighted)(shares)	72	72	71	66	59	58	58	58	58	59	62	63	63	63	63	63	63	63	63	62	62	58	55	54	51	49	49	49	49	49	48	48	48	46	44	44	43	41	39	38
Shares Outstanding (Diluted, Weighted)(shares)	90	90	71	66	59	58	58	58	58	59	62	63	63	63	63	63	63	63	63	62	62	58	55	54	51	49	49	49	49	49	48	48	48	46	44	44	43	41	39	38
EBITDA	0.27	-17	-29	-26	-32	-35	-33	-35	-59	-39	-40	-48	-41	-36	-40	-50	-37	-35	-43	-45	-33	-25	-27	-23	-23	-11	-8.89	-19	-18	-35	-30	-27	-14	-4.97	-12	-13	-12	-12	-11	-19

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 2.2%

Financial strength

Current ratio: 1.95
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –